Connect Biopharma to Present at Two Upcoming Investor Conferences
Connect Biopharma (Nasdaq: CNTB), a clinical-stage biopharmaceutical company specializing in Asthma and COPD treatments, has announced its participation in two major investor conferences in March 2025.
The company will present at the Leerink Partners Global Biopharma Conference on March 12, 2025, at 1:40 p.m. ET, and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, at 2:30 p.m. ET. Both presentations will be in a fireside chat format.
Live webcasts will be available on Connect's investor relations website, with archived replays accessible for approximately 90 days after the events.
Connect Biopharma (Nasdaq: CNTB), un'azienda biofarmaceutica in fase clinica specializzata nel trattamento dell'asma e della BPCO, ha annunciato la sua partecipazione a due importanti conferenze per investitori a marzo 2025.
L'azienda presenterà alla Conferenza Globale Biopharma di Leerink Partners il 12 marzo 2025, alle 13:40 ET, e alla 3ª Conferenza Virtuale Annuale sulle Malattie Autoimmuni e Infiamatorie di H.C. Wainwright il 27 marzo 2025, alle 14:30 ET. Entrambe le presentazioni si svolgeranno in formato colloquio informale.
Le dirette streaming saranno disponibili sul sito web delle relazioni con gli investitori di Connect, con repliche archiviate accessibili per circa 90 giorni dopo gli eventi.
Connect Biopharma (Nasdaq: CNTB), una empresa biofarmacéutica en etapa clínica especializada en tratamientos para el asma y la EPOC, ha anunciado su participación en dos importantes conferencias de inversores en marzo de 2025.
La empresa presentará en la Conferencia Global de Biopharma de Leerink Partners el 12 de marzo de 2025, a la 1:40 p.m. ET, y en la 3ª Conferencia Virtual Anual sobre Enfermedades Autoinmunes e Inflamatorias de H.C. Wainwright el 27 de marzo de 2025, a las 2:30 p.m. ET. Ambas presentaciones se realizarán en formato de charla informal.
Las transmisiones en vivo estarán disponibles en el sitio web de relaciones con inversores de Connect, con repeticiones archivadas accesibles durante aproximadamente 90 días después de los eventos.
Connect Biopharma (Nasdaq: CNTB), 임상 단계의 생명공학 회사로 천식 및 COPD 치료를 전문으로 하며, 2025년 3월에 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 2025년 3월 12일 오후 1시 40분 ET에 Leerink Partners 글로벌 생명공학 회의에서 발표하고, 2025년 3월 27일 오후 2시 30분 ET에 H.C. Wainwright 제3회 자가면역 및 염증 질환 가상 회의에서 발표할 예정입니다. 두 발표 모두 대화 형식으로 진행됩니다.
라이브 웹캐스트는 Connect의 투자자 관계 웹사이트에서 제공되며, 이벤트 후 약 90일 동안 아카이브된 재생이 가능합니다.
Connect Biopharma (Nasdaq: CNTB), une entreprise biopharmaceutique en phase clinique spécialisée dans les traitements de l'asthme et de la BPCO, a annoncé sa participation à deux grandes conférences pour investisseurs en mars 2025.
L'entreprise présentera lors de la Conférence Biopharma Mondiale de Leerink Partners le 12 mars 2025 à 13h40 ET, et lors de la 3ème Conférence Virtuelle Annuelle sur les Maladies Auto-immunes et Inflammatoires de H.C. Wainwright le 27 mars 2025 à 14h30 ET. Les deux présentations se dérouleront sous forme de discussion informelle.
Des webinaires en direct seront disponibles sur le site des relations avec les investisseurs de Connect, avec des rediffusions archivées accessibles pendant environ 90 jours après les événements.
Connect Biopharma (Nasdaq: CNTB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Asthma- und COPD-Behandlungen spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 bekannt gegeben.
Das Unternehmen wird am 12. März 2025 um 13:40 Uhr ET auf der Leerink Partners Global Biopharma Conference präsentieren und am 27. März 2025 um 14:30 Uhr ET auf der 3. jährlichen virtuellen Konferenz zu Autoimmun- und Entzündungserkrankungen von H.C. Wainwright. Beide Präsentationen werden im Format eines informellen Gesprächs stattfinden.
Live-Übertragungen werden auf der Website für Investorenbeziehungen von Connect verfügbar sein, mit archivierten Wiederholungen, die etwa 90 Tage nach den Veranstaltungen zugänglich sind.
- None.
- None.
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in Asthma and Chronic Obstructive Pulmonary Disease (COPD), today announced that company management will participate in the following upcoming conferences:
Leerink Partners Global Biopharma Conference
Format: Fireside Chat
Date: Wednesday, March 12, 2025
Time: 1:40 p.m. ET
Webcast Link: Register Here
H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Format: Fireside Chat
Date: Thursday, March 27, 2025
Time: 2:30 p.m. ET
Webcast Link: Register Here
Live webcasts for the events will also be accessible on Connect’s website in the Investors section under Presentations, Events & News at investors.connectbiopharm.com. An archived replay of the webcasts will be available for approximately 90 days following the event.
About Connect Biopharma
Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on advancing Rademikibart™, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform care in Asthma and COPD. Rademikibart has the potential to drive significant chronic utilization in Asthma and COPD with an initial focus on acute indications, which represent an untapped opportunity targeting the ~1 million asthma and ~1.3 million COPD patients in the U.S. alone who experience acute exacerbations annually. Rademikibart has demonstrated encouraging efficacy and safety in Phase 2 studies, as well as rapid onset of action as early as 24 hours. Learn more at www.connectbiopharm.com.
Investor Relations & Media Contact:
David Szekeres
President
Connect Biopharma
dszekeres@connectpharm.com
FAQ
When is Connect Biopharma (CNTB) presenting at the Leerink Partners Conference in March 2025?
What type of presentation format will CNTB use at the March 2025 investor conferences?
How long will CNTB's conference webcasts be available for replay?
What therapeutic areas does Connect Biopharma (CNTB) focus on?
When is CNTB presenting at the H.C. Wainwright Conference in March 2025?
